Fruquintinib & Sintilimab Trial Meets Primary Endpoint in Advanced RCC
HUTCHMED and Innovent Biologics announced positive top-line results from the FRUSICA-2 Phase II/III trial. The trial investigated fruquintinib combined...
Ocu200 DME Trial: Cohort 2 Dosing Approved After Safety Review
Ocugen, a biotechnology company, announced positive safety data from the first cohort of its Phase 1 clinical trial for...
Clearmind Medicine Initiates First Human Trial for Alcohol Use Disorder
Clearmind Medicine Inc. has initiated a Phase I/IIa clinical trial for CMND-100, a novel psychedelic-derived treatment for Alcohol Use...
Angitia Biopharmaceuticals Presents Promising Phase 1/2 Study Data of AGA111 at AAOS
Angitia Biopharmaceuticals announced positive Phase 1/2 trial data for AGA111, a recombinant human bone morphogenetic protein 6 (rhBMP6) designed...
Prime Medicine Unveils AATD Gene Correction Treatment Program
Prime Medicine announced a preclinical program for alpha-1 antitrypsin deficiency (AATD), using its prime editing technology delivered via a...
Bio-Path Holdings Announces Promising Pre-clinical Results for BP1001-A in Obesity Treatment for Type 2 Diabetes Patients
Bio-Path Holdings announced positive pre-clinical results for BP1001-A, a potential obesity treatment. The drug candidate successfully reversed fatty acid-induced...
2025 SCOPE Summit: Advancing Patient-Centric Clinical Trials
The 2025 SCOPE Summit brought together industry leaders to explore patient-centric approaches in clinical trials, addressing the critical issue...
Deramiocel Shows Long-Term Efficacy in Duchenne Muscular Dystrophy Treatment
Capricor Therapeutics announced positive three-year data from its open-label extension of the HOPE-2 clinical trial for deramiocel, a cell-based...
Cellphire Therapeutics gets FDA Fast Track for CLPH-511
Cellphire Therapeutics has received FDA Fast Track Designation for CLPH-511, a frozen activated platelet injectable suspension designed to treat...
PEP-010 Awarded FDA Orphan Drug Status for Pancreatic Cancer
PEP-Therapy’s lead product, PEP-010, a first-in-class bifunctional therapeutic peptide, received Orphan Drug Designation from the FDA for the treatment...